PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24919863-2	2014	In the EU, subcutaneous certolizumab pegol is indicated for the treatment of adults with severe active axial spondyloarthritis (axSpA), comprising ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), and for adults with active psoriatic arthritis (PsA).	Certolizumab Pegol	24-42	aminopeptidase puromycin sensitive	Homo sapiens	262-265	
24919863-5	2014	In two ongoing, well-designed studies, data at 12 and 24 weeks showed that treatment with certolizumab pegol (200 mg every 2 weeks or 400 mg every 4 weeks) was effective in improving the clinical signs and symptoms of disease, health-related quality of life and productivity in patients with axSpA (the RAPID-axSpA study) or PsA (the RAPID-PsA study), with the improvements maintained during longer-term (48 weeks) treatment.	Certolizumab Pegol	90-108	aminopeptidase puromycin sensitive	Homo sapiens	325-328	
24919863-5	2014	In two ongoing, well-designed studies, data at 12 and 24 weeks showed that treatment with certolizumab pegol (200 mg every 2 weeks or 400 mg every 4 weeks) was effective in improving the clinical signs and symptoms of disease, health-related quality of life and productivity in patients with axSpA (the RAPID-axSpA study) or PsA (the RAPID-PsA study), with the improvements maintained during longer-term (48 weeks) treatment.	Certolizumab Pegol	90-108	aminopeptidase puromycin sensitive	Homo sapiens	334-349	
24919863-7	2014	In addition, 12 weeks" treatment with certolizumab pegol reduced inflammation in the sacroiliac joints and spine in patients with axSpA and 24 weeks" treatment with the agent slowed radiographic disease progression in patients with PsA.	Certolizumab Pegol	38-50	aminopeptidase puromycin sensitive	Homo sapiens	232-235